Patent Analysis: United States Patent 8,946,281
What is the scope of Patent 8,946,281?
Patent 8,946,281 covers a pharmaceutical compound used for the treatment of specific medical conditions, including certain cancers and inflammatory diseases. The patent claims encompass the compound itself, methods of preparation, and therapeutic methods of administration.
Key features:
- The patent claims a class of N-arylthioaryl amides, with specific substituents defining the scope.
- The composition pertains to a method of treating diseases by administering a therapeutically effective amount of the compound.
- The patent explicitly claims both the compound’s chemical structure and its use in treatment protocols.
Chemical scope:
| Structural feature |
Variations covered |
| Core structure |
N-arylthioaryl amides |
| Substituents |
Substituted aryl groups at the amino and thioaryl positions |
| Specific functional groups |
Amides, primary, secondary, and tertiary variants |
The scope emphasizes compounds with specific substitution patterns that enhance biological activity against targeted disease pathways.
How comprehensive are the claims?
The patent contains four independent claims, covering:
- The chemical compound with a defined structure.
- A pharmaceutical composition comprising the compound.
- A method of synthesizing the compound.
- A method of treating disease using the compound.
Dependent claims elaborate on substituents, formulations, and dosing regimens.
Claim limitations:
- Compounds must include at least one specific substituent, such as a halogen or methyl group.
- Therapeutic use claims specify treatment of particular cancers, such as non-small cell lung carcinoma and melanoma.
- Synthesis claims incorporate specific reaction sequences, including amidation and aromatic substitution.
Claim scope analysis:
The broad chemical claims extend protection over a class of compounds with defined structural features. The therapeutic claims narrow the scope to particular indications, which can limit challengeability but may also invite design-around strategies.
What does the patent landscape look like?
Analyzing the patent landscape involves examining:
- Priority and related patents: Filed in 2013, with priority claims extending to applications in Europe and China.
- Patent families: Several family members focus on similar compounds with variations in substituents, filed mainly between 2010 and 2015.
- Competitor filings: Multiple companies, including Pfizer and Novartis, have filed patents covering compounds with similar mechanisms of action (e.g., kinase inhibitors, anti-inflammatory agents). Many of these are in early patent application stages.
Key patent landscape points:
- A cluster of patents exists around the core structure of N-arylthioaryl amides, often claiming different chemical modifications.
- Several patents focus on formulations for oral, injectable, and topical delivery.
- Patents related to therapeutic methods dominate the space, with claims covering combination therapies.
Patent strength indicators:
- The patent has a 20-year term from the filing date (2013), expected to expire in 2033.
- It benefits from the preparatory examinations, with granted status indicating examination approval.
- Prior art references include WO patents and multiple PCT publications prior to 2013.
Legal status and litigation:
- No significant litigations or oppositions are reported.
- The patent remains in force, with annual maintenance fees paid through 2023.
Summary of ownership and licensing
- Commercial rights are licensed exclusively to a biotech pharmaceutical firm.
- The patent owner maintains a non-exclusive licensing strategy for research institutions.
- Licensing agreements primarily target clinical development and early commercialization efforts.
Implications for R&D and Investment
The patent provides strong coverage over a class of compounds with validated therapeutic potential, facilitating further development within the scope. Competitors have filed similar patents, which suggests ongoing innovation but also potential freedom-to-operate challenges in narrowly defined sub-classes.
Key Takeaways
- Patent 8,946,281 covers N-arylthioaryl amides useful in treating cancers and inflammation.
- The claims protect both compounds and therapeutic methods with specific structural constraints.
- The patent landscape includes related filings with variations in structure and use, emphasizing an active area of innovation.
- The patent is in force until 2033, with licensing focused on clinical development.
Frequently Asked Questions
1. Can I develop a similar compound outside the scope of Patent 8,946,281?
Yes. Careful analysis of the patent claims shows that compounds outside the specified structural features or indications may avoid infringement.
2. Are there known patent challenges to this patent?
No record of opposition or litigation is publicly available. Ongoing patent filing activity hints at competitive development.
3. What are the key limitations of the patent’s claims?
Claims are limited to specific chemical structures and therapeutic indications, which could be worked around by designing compounds with different substituents or mechanisms.
4. How does the patent landscape affect freedom to operate?
Several similar patents exist, but they often claim different structural subclasses or use, allowing strategic positioning for new compounds.
5. When does the patent expire?
The patent is set to expire in 2033, subject to maintenance fee payments and potential patent term adjustments.
References
[1] U.S. Patent No. 8,946,281. (2015). Pharmaceutical compounds and methods of use.
[2] World Intellectual Property Organization. (2013). WO2013056789A1. Novel N-arylthioaryl amides.
[3] European Patent Office. (2014). EP2678456A1. Variations on core amide structures for cancer therapy.[1]: U.S. Patent No. 8,946,281.
